Development of full human monoclonal Ab to human TRAIL-Rs for tumor therapy / 实用肿瘤学杂志
Practical Oncology Journal
;
(6): 344-348, 2014.
Article
in Chinese
| WPRIM
| ID: wpr-499217
ABSTRACT
Monoclonal antibodies(mAbs)to human TRAIL receptors(TRAIL-Rs)have been developed in tumor targeted therapy and currently used in clinical Ⅰ~Ⅳtrials.MAbs can bind death-receptors(TRAIL-R1 and TRAIL-R2)and then results in formation of the death inducing signaling complex (DISC)and apoptosis of tumor cells.TRAIL -Rs mAbs have become one of the research and development hotspots of anti -tumor drugs.These mAbs have achieved remarkable results in combination with radio -or chemo-therapy drugs or oth-er agents and immunotherapy in the treatment of tumor and offer a new therapeutic strategy for clinical tumor treatment.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Practical Oncology Journal
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS